… As an employer, we value a diverse workforce in which people are encouraged to develop themselves both personally and professionally. We … • 30 vacation days. • An annual performance bonus. • Stock options. • A premium-free pension plan. • A commuting …
… for our liver programs, driving the discovery and development of novel RNA-based drug candidates for chronic … Science, and the Chief Scientific Officer to identify and develop new opportunities, optimize our portfolio, and ensure scientific …
… As an employer, we value a diverse workforce in which people are encouraged to develop themselves both personally and professionally. We … 30 vacation days An annual performance bonus Stock options A premium-free pension plan A commuting allowance A …
Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 P
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief